Non-small cell lung cancer (NSCLC) is one of the most deadly diseases and is affecting a large number of people all over the world. In the recent years, an increased interest has been developed in the concept of Oligometastatic disease in NSCLC. Oligometastatic disease is defined as the cancer that has spread to a limited number of sites. It refers to the presence of a solitary site of metastasis, representing aggressive form of metastatic cancer.
Recent work in the arena of lung cancer has proven the existence of Oligometastatic state in NSCLC in terms of patients who may benefit from aggressive therapy. Oligometastatic disease is found in approximately 7% of patients who are newly diagnosed with NSCLC. There are potential treatment options available for Oligometastatic non-small cell lung cancer, ranging from upfront systemic therapy and local treatment to systematic therapy and more.
One of the common treatment strategies for oligometastatic NSCLC is upfront systematic therapy. Then, there’s surgical management of oligometastatic NSCLC as well which is limited to patients who are deemed to be medically operable with anatomically primary tumors. The patients could also be given combination of surgery or radiation. Though the search for evidence of oligometastatic non-small cell lung cancer has been relevant but a lot of more work needs to be done. There appears to be an oligometastatic disease state in select patients with NSCLC such as controlled primary tumors, limited nodal burden etc. Although the understanding of oligometastatic has progressed significantly over the recent decades, there’s much more to be learned and discovered. The studies help to improve patient outcomes and confidently conclude that the disease exists and it can be cured.
The information shared in this blog is for educational purposes only. If you have any issues, you should contact your doctor immediately.